Literature DB >> 20472893

Bisphosphonates cause osteonecrosis of the jaw-like disease in mice.

Yanming Bi1, Yamei Gao, Driss Ehirchiou, Chunzhang Cao, Takashi Kikuiri, Anh Le, Songtao Shi, Li Zhang.   

Abstract

Bisphosphonate-associated osteonecrosis of the jaw (BONJ) is a morbid bone disease linked to long-term bisphosphonate use. Despite its broad health impact, mechanistic study is lacking. In this study, we have established a mouse model of BONJ-like disease based on the equivalent clinical regimen in myeloma patients, a group associated with high risk of BONJ. We demonstrate that the murine BONJ-like disease recapitulates major clinical and radiographical manifestations of the human disease, including characteristic features of osseous sclerosis, sequestra, avascular, and radiopaque alveolar bone in the jaw that persists beyond a normal course of wound healing following tooth extraction. We find that long-term administration of bisphosphonates results in an increase in the size and number of osteoclasts and the formation of giant osteoclast-like cells within the alveolar bone. We show that the development of necrotic bone and impaired soft tissue healing in our mouse model is dependent on long-term use of high-dose bisphosphonates, immunosuppressive and chemotherapy drugs, as well as mechanical trauma. Most importantly, we demonstrate that bisphosphonate is the major cause of BONJ-like disease in mice, mediated in part by its ability to suppress osseous angiogenesis and bone remodeling. The availability of this novel mouse model of BONJ-like disease will help elucidate the pathophysiology of BONJ and ultimately develop novel approaches for prevention and treatment of human BONJ.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20472893      PMCID: PMC2893671          DOI: 10.2353/ajpath.2010.090592

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  26 in total

1.  Reports of adverse events from bone drugs prompt caution.

Authors:  Bridget M Kuehn
Journal:  JAMA       Date:  2006-06-28       Impact factor: 56.272

2.  American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws.

Authors: 
Journal:  J Oral Maxillofac Surg       Date:  2007-03       Impact factor: 1.895

3.  Blood vessels form a scaffold for neuroblast migration in the adult olfactory bulb.

Authors:  Serena Bovetti; Yi-Chun Hsieh; Patrizia Bovolin; Isabelle Perroteau; Toida Kazunori; Adam C Puche
Journal:  J Neurosci       Date:  2007-05-30       Impact factor: 6.167

Review 4.  Docetaxel: a review of its use in metastatic breast cancer.

Authors:  Katherine A Lyseng-Williamson; Caroline Fenton
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells.

Authors:  Fabian von Knoch; Claude Jaquiery; Marc Kowalsky; Stefan Schaeren; Claude Alabre; Ivan Martin; Harry E Rubash; Arun S Shanbhag
Journal:  Biomaterials       Date:  2005-12       Impact factor: 12.479

Review 6.  Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease.

Authors:  Colin R Dunstan; Dieter Felsenberg; Markus J Seibel
Journal:  Nat Clin Pract Oncol       Date:  2007-01

7.  Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis.

Authors:  Torsten Hansen; Martin Kunkel; Achim Weber; C James Kirkpatrick
Journal:  J Oral Pathol Med       Date:  2006-03       Impact factor: 4.253

Review 8.  Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws.

Authors:  Sook-Bin Woo; John W Hellstein; John R Kalmar
Journal:  Ann Intern Med       Date:  2006-05-16       Impact factor: 25.391

9.  Identification of tendon stem/progenitor cells and the role of the extracellular matrix in their niche.

Authors:  Yanming Bi; Driss Ehirchiou; Tina M Kilts; Colette A Inkson; Mildred C Embree; Wataru Sonoyama; Li Li; Arabella I Leet; Byoung-Moo Seo; Li Zhang; Songtao Shi; Marian F Young
Journal:  Nat Med       Date:  2007-09-09       Impact factor: 53.440

10.  Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research.

Authors:  Sundeep Khosla; David Burr; Jane Cauley; David W Dempster; Peter R Ebeling; Dieter Felsenberg; Robert F Gagel; Vincente Gilsanz; Theresa Guise; Sreenivas Koka; Laurie K McCauley; Joan McGowan; Marc D McKee; Suresh Mohla; David G Pendrys; Lawrence G Raisz; Salvatore L Ruggiero; David M Shafer; Lillian Shum; Stuart L Silverman; Catherine H Van Poznak; Nelson Watts; Sook-Bin Woo; Elizabeth Shane
Journal:  J Bone Miner Res       Date:  2007-10       Impact factor: 6.741

View more
  61 in total

1.  Osteomalacia: the missing link in the pathogenesis of bisphosphonate-related osteonecrosis of the jaws?

Authors:  Alberto Bedogni; Giorgia Saia; Giordana Bettini; Anita Tronchet; Andrea Totola; Giorgio Bedogni; Paolo Tregnago; Maria Teresa Valenti; Francesco Bertoldo; Giuseppe Ferronato; Pier Francesco Nocini; Stella Blandamura; Luca Dalle Carbonare
Journal:  Oncologist       Date:  2012-06-20

2.  Odanacatib, A Cathepsin K-Specific Inhibitor, Inhibits Inflammation and Bone Loss Caused by Periodontal Diseases.

Authors:  Liang Hao; Jianwei Chen; Zheng Zhu; Michael S Reddy; John D Mountz; Wei Chen; Yi-Ping Li
Journal:  J Periodontol       Date:  2015-04-16       Impact factor: 6.993

3.  OPG-Fc but Not Zoledronic Acid Discontinuation Reverses Osteonecrosis of the Jaws (ONJ) in Mice.

Authors:  Rafael Scaf de Molon; Hiroaki Shimamoto; Olga Bezouglaia; Flavia Q Pirih; Sarah M Dry; Paul Kostenuik; Rogely W Boyce; Denise Dwyer; Tara L Aghaloo; Sotirios Tetradis
Journal:  J Bone Miner Res       Date:  2015-05-27       Impact factor: 6.741

Review 4.  Bisphosphonate-related osteonecrosis of the jaw in non-malignant bone disease.

Authors:  Peter K Wong; Gelsomina L Borromeo; John D Wark
Journal:  Rheumatol Int       Date:  2013-05-08       Impact factor: 2.631

5.  Combined zoledronic acid and meloxicam reduced bone loss and tumour growth in an orthotopic mouse model of bone-invasive oral squamous cell carcinoma.

Authors:  C K Martin; W P Dirksen; M M Carlton; L G Lanigan; S P Pillai; J L Werbeck; J K Simmons; B E Hildreth; C A London; R E Toribio; T J Rosol
Journal:  Vet Comp Oncol       Date:  2013-05-08       Impact factor: 2.613

6.  Spontaneous osteonecrosis of the jaws in the maxilla of mice on antiresorptive treatment: a novel ONJ mouse model.

Authors:  Rafael Scaf de Molon; Simon Cheong; Olga Bezouglaia; Sarah M Dry; Flavia Pirih; Joni Augusto Cirelli; Tara L Aghaloo; Sotirios Tetradis
Journal:  Bone       Date:  2014-08-02       Impact factor: 4.398

7.  Periapical disease and bisphosphonates induce osteonecrosis of the jaws in mice.

Authors:  Ben Kang; Simon Cheong; Thawinee Chaichanasakul; Olga Bezouglaia; Elisa Atti; Sarah M Dry; Flavia Q Pirih; Tara L Aghaloo; Sotirios Tetradis
Journal:  J Bone Miner Res       Date:  2013-07       Impact factor: 6.741

8.  Nitrogen-containing bisphosphonate therapy-Part II: Assessment of alveolar bone tissue inflammatory response in rats-A blind randomized controlled trial.

Authors:  Viviane N Pacheco; Renan Langie; Jules R D Benfica; Jéssica C Munaretto; Adriana Etges; Deise Ponzoni; Edela Puricelli
Journal:  Int J Exp Pathol       Date:  2018-11-20       Impact factor: 1.925

9.  IL-36 Induces Bisphosphonate-Related Osteonecrosis of the Jaw-Like Lesions in Mice by Inhibiting TGF-β-Mediated Collagen Expression.

Authors:  Sol Kim; Drake W Williams; Cindy Lee; Terresa Kim; Atsushi Arai; Songtao Shi; Xinmin Li; Ki-Hyuk Shin; Mo K Kang; No-Hee Park; Reuben H Kim
Journal:  J Bone Miner Res       Date:  2016-10-12       Impact factor: 6.741

10.  Tooth extraction in mice administered zoledronate increases inflammatory cytokine levels and promotes osteonecrosis of the jaw.

Authors:  Tomoya Soma; Ryotaro Iwasaki; Yuiko Sato; Tami Kobayashi; Satoshi Nakamura; Yosuke Kaneko; Eri Ito; Hiroyuki Okada; Hisato Watanabe; Kana Miyamoto; Morio Matsumoto; Masaya Nakamura; Seiji Asoda; Hiromasa Kawana; Taneaki Nakagawa; Takeshi Miyamoto
Journal:  J Bone Miner Metab       Date:  2020-11-17       Impact factor: 2.626

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.